1. Home
  2. SDEV vs GRDX Comparison

SDEV vs GRDX Comparison

Compare SDEV & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDEV

Stablecoin Development Corporation Common Stock

N/A

Current Price

$1.16

Market Cap

33.1M

Sector

Health Care

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$2.95

Market Cap

28.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDEV
GRDX
Founded
N/A
N/A
Country
United States
United Kingdom
Employees
4
2
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.1M
28.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SDEV
GRDX
Price
$1.16
$2.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
169.3K
60.4K
Earning Date
N/A
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$1.87
52 Week High
$1.60
$6.93

Technical Indicators

Market Signals
Indicator
SDEV
GRDX
Relative Strength Index (RSI) 49.57 38.29
Support Level $1.05 $2.01
Resistance Level $1.58 $3.65
Average True Range (ATR) 0.08 0.40
MACD -0.01 -0.05
Stochastic Oscillator 32.68 26.79

Price Performance

Historical Comparison
SDEV
GRDX

About SDEV Stablecoin Development Corporation Common Stock

Stablecoin Development Corp is an on-chain holding company focused on long-duration participation in protocol-aligned digital asset ecosystems. The Company's initial digital asset focus is the Sky protocol ecosystem, with SKY as its core holding. Through staking and other on-chain activities, the Company seeks to generate protocol-level economic returns while maintaining rigorous governance and risk management oversight.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: